1
|
Somasundaram V, Ridnour LA, Cheng RY, Walke AJ, Kedei N, Bhattacharyya DD, Wink AL, Edmondson EF, Butcher D, Warner AC, Dorsey TH, Scheiblin DA, Heinz W, Bryant RJ, Kinders RJ, Lipkowitz S, Wong ST, Pore M, Hewitt SM, McVicar DW, Anderson SK, Chang J, Glynn SA, Ambs S, Lockett SJ, Wink DA. Systemic Nos2 Depletion and Cox inhibition limits TNBC disease progression and alters lymphoid cell spatial orientation and density. Redox Biol 2022; 58:102529. [PMID: 36375380 PMCID: PMC9661390 DOI: 10.1016/j.redox.2022.102529] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Revised: 10/21/2022] [Accepted: 10/31/2022] [Indexed: 11/10/2022] Open
Abstract
Antitumor immune polarization is a key predictor of clinical outcomes to cancer therapy. An emerging concept influencing clinical outcome involves the spatial location of CD8+ T cells, within the tumor. Our earlier work demonstrated immunosuppressive effects of NOS2 and COX2 tumor expression. Here, we show that NOS2/COX2 levels influence both the polarization and spatial location of lymphoid cells including CD8+ T cells. Importantly, elevated tumor NOS2/COX2 correlated with exclusion of CD8+ T cells from the tumor epithelium. In contrast, tumors expressing low NOS2/COX2 had increased CD8+ T cell penetration into the tumor epithelium. Consistent with a causative relationship between these observations, pharmacological inhibition of COX2 with indomethacin dramatically reduced tumor growth of the 4T1 model of TNBC in both WT and Nos2- mice. This regimen led to complete tumor regression in ∼20-25% of tumor-bearing Nos2- mice, and these animals were resistant to tumor rechallenge. Th1 cytokines were elevated in the blood of treated mice and intratumoral CD4+ and CD8+ T cells were higher in mice that received indomethacin when compared to control untreated mice. Multiplex immunofluorescence imaging confirmed our phenotyping results and demonstrated that targeted Nos2/Cox2 blockade improved CD8+ T cell penetration into the 4T1 tumor core. These findings are consistent with our observations in low NOS2/COX2 expressing breast tumors proving that COX2 activity is responsible for limiting the spatial distribution of effector T cells in TNBC. Together these results suggest that clinically available NSAID's may provide a cost-effective, novel immunotherapeutic approach for treatment of aggressive tumors including triple negative breast cancer.
Collapse
Affiliation(s)
- Veena Somasundaram
- Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
| | - Lisa A Ridnour
- Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
| | - Robert Ys Cheng
- Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
| | - Abigail J Walke
- Optical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, Frederick, MD, USA
| | - Noemi Kedei
- Collaborative Protein Technology Resource Nanoscale Protein Analysis, Office of Science Technology Resources, CCR, NCI, NIH, Bethesda, MD, USA
| | - Dibyangana D Bhattacharyya
- Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
| | - Adelaide L Wink
- Optical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, Frederick, MD, USA
| | - Elijah F Edmondson
- Molecular Histopathology Laboratories, Leidos Biomedical Research Inc. for NCI, Frederick, MD, USA
| | - Donna Butcher
- Molecular Histopathology Laboratories, Leidos Biomedical Research Inc. for NCI, Frederick, MD, USA
| | - Andrew C Warner
- Molecular Histopathology Laboratories, Leidos Biomedical Research Inc. for NCI, Frederick, MD, USA
| | - Tiffany H Dorsey
- Laboratory of Human Carcinogenesis, CCR, NCI, NIH, Bethesda, MD, USA
| | - David A Scheiblin
- Optical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, Frederick, MD, USA
| | - William Heinz
- Optical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, Frederick, MD, USA
| | - Richard J Bryant
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
| | - Robert J Kinders
- Office of the Director, Division of Cancer Treatment and Diagnosis, NCI, Frederick, MD, USA
| | | | - Stephen Tc Wong
- Systems Medicine and Bioengineering, Houston Methodist Neal Cancer Center and Weill Cornell Medical College, Houston, TX, USA
| | - Milind Pore
- Imaging Mass Cytometry Frederick National Laboratory for Cancer Research, USA
| | | | - Daniel W McVicar
- Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA
| | - Stephen K Anderson
- Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
| | - Jenny Chang
- Mary and Ron Neal Cancer Center, Houston Methodist Weill Cornell Medical College, Houston, TX, USA
| | - Sharon A Glynn
- Discipline of Pathology, Lambe Institute for Translational Research, School of Medicine, University of Galway, Galway, H91 TK33, Ireland
| | - Stefan Ambs
- Laboratory of Human Carcinogenesis, CCR, NCI, NIH, Bethesda, MD, USA
| | - Stephen J Lockett
- Optical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, Frederick, MD, USA.
| | - David A Wink
- Cancer Innovation Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
| |
Collapse
|
2
|
Das B, Evrard YA, Chen L, Patidar R, Vilimas T, McCutcheon JN, Peach AL, Nair NV, Forbes TD, Fullmer BA, Fong AJL, Romero LE, Chapman AK, Conley KA, Harrington RD, Jiwani SS, Wang P, Gottholm-Ahalt MM, Cantu EN, Rivera G, Dutko LM, Benauer KM, Kannan VR, Bonomi CA, Dougherty KM, Geraghty JP, Gibson MV, Styers SS, Walke AJ, Moyer JE, Wade A, Baldwin ML, Arthur KA, Plater KJ, Stockwin L, Murphy MR, Mullendore ME, Newton DL, Hollingshead MG, Karlovich CA, Williams PM, Doroshow JH. Abstract 3916: Patient-derived organoid and cell culture models from the NCI Patient-Derived Models Repository (NCI PDMR) preserve genomic stability and heterogeneity of patient tumor specimens. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-3916] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The National Cancer Institute (NCI) has developed a Patient-Derived Models Repository (PDMR; https://pdmr.cancer.gov) of preclinical models including patient-derived xenografts (PDX), organoids (PDOrg) and patient-derived cell cultures (PDC). Extensive clinical annotation and genomic datasets are available for these preclinical models. However, it is unclear if the molecular profiles of the corresponding patient tumors are stably propagated in these models. We have previously demonstrated that PDX models from the NCI PDMR faithfully represent the patient tumors both in terms of genomic stability and tumor heterogeneity. Here, we conduct an in-depth investigation of genomic representation of patient tumors in the PDOrgs and PDCs.
Methods: PDOrgs (n=64) and PDCs (n=94) were established from tumor fragments (i.e., initiator specimens) obtained either from patient specimens or from PDX specimens of early passage. For some models (n=19), both PDOrgs and PDCs were generated from the same tumor tissue; in fewer cases (n=4), PDCs were established from organoids derived from patient specimens. Whole Exome Sequencing and RNA-Seq were performed on all PDCs and PDOrgs, and data were compared with patient specimens or early passage PDXs.
Results: A majority of the PDOrgs and PDCs have stably inherited the genome of the corresponding patient specimens based on the following observations: (1) >87% of PDOrgs and PDCs maintained similar copy number alteration profiles compared with the initiator specimens of the preclinical model; (2) the variant allele frequency (VAF) of clinically relevant mutations remained consistent between the PDOrgs, PDCs, and the initiator specimens, with none of the PDCs or PDOrgs deviating by >15% VAF; and (3) clinically relevant biomarkers (e.g., MSI, LOH, mutational signatures etc.) are concordant amongst the PDOrgs, PDCs, and the initiator specimens. We observed that the majority of SNVs and indels present in the initiator specimens were also found in the PDOrgs and PDCs, suggesting almost all the tumor heterogeneity was preserved in these preclinical models.
Conclusions: This large and histologically diverse set of PDOrgs and PDCs from the NCI PDMR exhibited genomic stability and faithfully represented the tumor heterogeneity observed in corresponding patient specimens. These preclinical models thus represent a valuable resource for researchers interested in pre-clinical drug or other studies.
Citation Format: Biswajit Das, Yvonne A. Evrard, Li Chen, Rajesh Patidar, Tomas Vilimas, Justine N. McCutcheon, Amanda L. Peach, Nikitha V. Nair, Thomas D. Forbes, Brandie A. Fullmer, Anna J. Lee Fong, Luis E. Romero, Alyssa K. Chapman, Kelsey A. Conley, Robin D. Harrington, Shahanawaz S. Jiwani, Peng Wang, Michelle M. Gottholm-Ahalt, Erin N. Cantu, Gloryvee Rivera, Lindsay M. Dutko, Kelly M. Benauer, Vishnuprabha R. Kannan, Carrie A. Bonomi, Kelly M. Dougherty, Joseph P. Geraghty, Marion V. Gibson, Savanna S. Styers, Abigail J. Walke, Jenna E. Moyer, Anna Wade, Mariah L. Baldwin, Kaitlyn A. Arthur, Kevin J. Plater, Luke Stockwin, Matthew R. Murphy, Michael E. Mullendore, Dianne L. Newton, Melinda G. Hollingshead, Chris A. Karlovich, Paul M. Williams, James H. Doroshow. Patient-derived organoid and cell culture models from the NCI Patient-Derived Models Repository (NCI PDMR) preserve genomic stability and heterogeneity of patient tumor specimens [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3916.
Collapse
Affiliation(s)
- Biswajit Das
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Yvonne A. Evrard
- 2Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Li Chen
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Rajesh Patidar
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Tomas Vilimas
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Justine N. McCutcheon
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Amanda L. Peach
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Nikitha V. Nair
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Thomas D. Forbes
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Brandie A. Fullmer
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Anna J. Lee Fong
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Luis E. Romero
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Alyssa K. Chapman
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Kelsey A. Conley
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Robin D. Harrington
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Shahanawaz S. Jiwani
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Peng Wang
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Michelle M. Gottholm-Ahalt
- 3Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD
| | - Erin N. Cantu
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Gloryvee Rivera
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Lindsay M. Dutko
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Kelly M. Benauer
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Vishnuprabha R. Kannan
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Carrie A. Bonomi
- 2Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | | | | | - Marion V. Gibson
- 2Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Savanna S. Styers
- 2Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Abigail J. Walke
- 2Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Jenna E. Moyer
- 2Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Anna Wade
- 2Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Mariah L. Baldwin
- 2Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Kaitlyn A. Arthur
- 2Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Kevin J. Plater
- 2Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Luke Stockwin
- 2Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Matthew R. Murphy
- 2Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | | | - Dianne L. Newton
- 2Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Melinda G. Hollingshead
- 3Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute at Frederick, Frederick, MD
| | - Chris A. Karlovich
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - Paul M. Williams
- 1Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research (NCI), Frederick, MD
| | - James H. Doroshow
- 4Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
| |
Collapse
|